Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 3,801–3,900 of 15,747
COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
Al-Jighefee, H. T., Najjar, H., Ahmed, M. N., Qush, A., Awwad, S., & Kamareddine, L. (2021) · Vaccines · doi:10.3390/vaccines9101196 · Cited by 36
“Preliminary results showed astoundingly 94–95% efficacy for both vaccines [88,89].”
BackgroundDesign of modular autoproteolytic gene switches responsive to anti-coronavirus drug candidates
Franko, N., Teixeira, A. P., Xue, S., Hamri, G. C., & Fussenegger, M. (2021) · Nature Communications · doi:10.1038/s41467-021-27072-3 · Cited by 27
“From the synTF containing the three native 2 NATURE COMMUNICATIONS | (2021) 12:6786 | https://doi.org/10.1038/s41467-021-27072-3 | www.nature.com/naturecommunications PLpro CSs, the PLproCSNAT1 based synTF showed the highest reporter expression level with only fourfold less secreted nanoLuc than the synTF lacking any…”
MethodInfluentialCOVID-19 diverse outcomes: Aggravated reinfection, type I interferons and antibodies
Silva, R. C. M. C., Bandeira‐Melo, C., Neto, H. A. P., Vale, A. M., & Travassos, L. H. (2022) · Medical Hypotheses · doi:10.1016/j.mehy.2022.110943 · Cited by 28
“the benefits related to the presence of antibodies after vaccination [65] do not support ADE as a hypothesis for aggravated reinfections or the genesis of SARS-CoV-2-mediated cytokine storm.”
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27
“Groups below 55 years of age reported a higher frequency of intense pain, fever and fatigue upon the second dose compared to older groups [103].”
BackgroundLim, J., Lee, S. A., Khil, E. K., Byeon, S., Kang, H. J., & Choi, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.10.002 · Cited by 28
COVID-19 in Liver Transplant Recipients: A Systematic Review
Becchetti, C., Gschwend, S. G., Dufour, J., & Banz, V. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10174015 · Cited by 28
“In December 2020, encouraging results on the safety and efficacy profile of the first antiSARS-CoV-2 vaccines were published [9,10], paving the way for a large-scale vaccination campaign.”
BackgroundScotta, M. C., & Stein, R. T. (2022) · Jornal de Pediatria · doi:10.1016/j.jped.2022.10.004 · Cited by 31
Kim, J. H., Kim, J. H., & Woo, C. G. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e91 · Cited by 28
Brinkkemper, M., Veth, T. S., Brouwer, P. J. M., Turner, H. L., Poniman, M., Burger, J. A., Bouhuijs, J. H., Olijhoek, W., Bontjer, I., Snitselaar, J. L., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105649 · Cited by 25
Sommerauer, C., & Kutter, C. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00232.2022 · Cited by 28
Heyne, S., Esser, P., Werner, A., Lehmann‐Laue, A., & Mehnert-Theuerkauf, A. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03961-y · Cited by 31
Bioengineering strategies to optimize STING agonist therapy
Dosta, P., Cryer, A. M., Prado, M., & Artzi, N. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00337-y · Cited by 35
“Additionally, synthetic polymers can exhibit inherent STING-activating properties, such as poly[(2-(hexamethyleneimino) ethyl methacrylate)-co- (butyl methacrylate)] (PC7A), which activates STING through the polymer-induced formation of STING–PC7A condensates.”
SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets
Shivshankar, P., Karmouty‐Quintana, H., Mills, T., Doursout, M., Wang, Y., Czopik, A. K., Evans, S. E., Eltzschig, H. K., & Yuan, X. (2022) · Inflammation · doi:10.1007/s10753-022-01656-7 · Cited by 30
Smith, M. R., Trofimova, M., Weber, A., Duport, Y., Kühnert, D., & von Kleist, M. (2021) · Nature Communications · doi:10.1038/s41467-021-26267-y · Cited by 30
Skrzat‐Klapaczyńska, A., Bieńkowski, C., Kowalska, J. D., Paciorek, M., Puła, J., Krogulec, D., Stengiel, J., Pawełczyk, A., Perlejewski, K., Osuch, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10040552 · Cited by 27
“2020, Poland introduced a mass vaccination program using the BNT162b2 mRNA vaccine (Pfizer-BioNTech) [6].”
BackgroundCOVID-19 Vaccination and Estimated Public Health Impact in California
Tan, S. T., Park, H. J., Rodríguez-Barraquer, I., Rutherford, G. W., Bibbins-Domingo, K. B., Schechter, R., & Lo, N. C. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8526 · Cited by 28
Unilateral axillary adenopathy induced by COVID-19 vaccine: US follow-up evaluation
Rouilleault, A. C. I., Soriano, I., Quan, P. L., Fernández‐Montero, A., Elizalde, A., & Pina, L. (2021) · European Radiology · doi:10.1007/s00330-021-08309-7 · Cited by 26
“Furthermore, studies of cell infiltration after mRNA vaccination show that the level of cell infiltration (neutrophils and APCs) at sites of injection seems to be at its highest 24 h after vaccination [7] so it is possible that cellular proliferation processes (which we equate with lymph node size) occur closer to the…”
Claudin 18.2—a FAST-moving target in gastric cancer?
Athauda, A., & Chau, I. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.021 · Cited by 26
Optimization of the 5ʹ untranslated region of mRNA vaccines
Ma, Q., Zhang, X., Yang, J., Li, H., Hao, Y., & Feng, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-70792-x · Cited by 38
Lo, S. P., Hsieh, T., Pastuszak, A. W., Hotaling, J. M., & Patel, D. P. (2021) · International Journal of Impotence Research · doi:10.1038/s41443-021-00483-y · Cited by 26
Analysis of Emerging Variants in Structured Regions of the SARS-CoV-2 Genome
Ryder, S. P., Morgan, B. R., Coskun, P., Antkowiak, K. R., & Massi, F. (2021) · Evolutionary Bioinformatics · doi:10.1177/11769343211014167 · Cited by 25
McLeod, D. V., & Gandon, S. (2022) · Nature Ecology & Evolution · doi:10.1038/s41559-022-01709-y · Cited by 28
Riccio, M. D., Bechini, A., Buscemi, P., Bonanni, P., On Behalf Of The Working Group Dhs, & Boccalini, S. (2022) · Vaccines · doi:10.3390/vaccines10060913 · Cited by 29
“It is important to mention that the willingness (and the hesitance) to vaccinate at the time this study was conducted may have been strongly influenced by the lack of data and information on this vaccine’s safety and efficacy: no study had been published yet, with the first one being issued one week after that the clo…”
BackgroundYamamoto, K., Mashiba, T., Takano, K., Suzuki, T., Kami, M., Takita, M., Kusumi, E., Mizuno, Y., & Hamaki, T. (2021) · Vaccines · doi:10.3390/vaccines9101108 · Cited by 28
“In a Phase III clinical trial on the BNT162b2 mRNA COVID-19 vaccine [1], 83% of vaccine recipients aged 16 to 55 years developed pain at injection sites, and 47% and 42% of them complained of fatigue and headache,”
BackgroundGan, L., Chen, Y., Tan, J., Wang, X., & Zhang, D. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07735-2 · Cited by 29
Buisson, Y. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104131 · Cited by 32
Gál, L., Bellák, T., Marton, A., Fekécs, Z., Weissman, D., Török, D. G., Biju, R., Vízler, C., Kristóf, R., Beattie, M. B., et al. (2023) · Research · doi:10.34133/research.0056 · Cited by 35
“Nucleoside-modified mRNA-LNP coronavirus disease 2019 (COVID-19) vaccines proved to be safe and effective in humans, opening the way for new applications of the platform such as protein replacement therapy and gene editing [22,23].”
BackgroundSikora, D., & Rzymski, P. (2022) · Vaccines · doi:10.3390/vaccines10030437 · Cited by 26
Choi, J. H., Kim, Y. R., Heo, S. T., Oh, H., Kim, M.-S., Lee, H. R., & Yoo, J. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.827306 · Cited by 29
“In a randomized controlled trial, the BNT162b2 mRNA vaccine (tozinameran, Pfizer-BioNTech) showed ≥95% efficacy against symptomatic and severe COVID-19 caused by SARS-CoV-2 (1).”
BackgroundEmergence of Post COVID-19 Vaccine Autoimmune Diseases: A Single Center Study
Alqatari, S. G., Ismail, M. H., Hasan, M. A., Bukhari, R., Argan, R. A., Alwaheed, A., Alkhafaji, D., Ahmed, S. E., Hadhiah, K. M., Alamri, T., et al. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s394602 · Cited by 26
“Vaccine trials were started in November 2020 and completed rapidly due to the urgency to get over the infection.(3) The first vaccine, Pfizer-BioNTech, was approved by the US Food and Drug Administration (FDA) in August 2020 and the rollout of vaccines started in December the same year.”
Lu, J., Liu, J., Wu, Y., He, X., Gao, X., Chen, X., Chen, S., Zhu, X., Peng, Y., Xiao, G., et al. (2024) · Journal of Virology · doi:10.1128/jvi.00769-24 · Cited by 30
“The efficacy and safety of mRNA vaccines have been substantiated through extensive real-world evidence, as exemplified during the coronavirus disease 2019 pandemic (30, 31), thereby affirming their potential for application against a broader range of pathogens.”
BackgroundCRISPR-based therapeutic genome editing for inherited blood disorders
Levesque, S., & Bauer, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01236-y · Cited by 39
“Pivotal discoveries, including the impact of mRNA nucleoside modification on the suppression of RNA recognition by Toll-like receptors 244 , enabled the development of life-saving mRNA vaccines 245,246 .”
Zhu, Z., Xu, L., & Chen, G. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1984135 · Cited by 27
Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines
Yıldız, A., Răileanu, C., & Beißert, T. (2024) · Viruses · doi:10.3390/v16040503 · Cited by 31
Manifestation of Herpetic Eye Disease after COVID-19 Vaccine: A UK Case Series
Rallis, K. I., Fausto, R., Ting, D. S. J., Al-Aqaba, M. A., Said, D. G., & Dua, H. S. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2046795 · Cited by 27
Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19
(2021) · doi:10.1101/2021.10.07.21264626 · Cited by 26
“These findings are consistent with those of the phase 2/3 clinical trial of the BNT162b2 vaccine 9 , where vaccine efficacy was similar across age groups.”
ResultIntawong, K., Chariyalertsak, S., Chalom, K., Wonghirundecha, T., Kowatcharakul, W., Thongprachum, A., Chotirosniramit, N., Teacharak, W., Khammawan, P., Waneesorn, J., et al. (2022) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2022.100121 · Cited by 37
HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine
Gutiérrez‐Bautista, J. F., Sampedro, A., Gómez-Vicente, E., Rodríguez‐Granger, J., Reguera, J. A., Cobo, F., Ruiz‐Cabello, F., & López‐Nevot, M. Á. (2022) · Vaccines · doi:10.3390/vaccines10030402 · Cited by 29
“However, the development of vaccines against the virus is vitally important to avoid serious illness and death [3,4].”
BackgroundInsights into SARS-CoV-2 evolution, potential antivirals, and vaccines
Abdel-Moneim, A. S., Abdelwhab, E. M., & Memish, Z. A. (2021) · Virology · doi:10.1016/j.virol.2021.02.007 · Cited by 29
Lafon, E., Jäger, M., Bauer, A., Reindl, M., Bellmann‐Weiler, R., Wilflingseder, D., Lass‐Flörl, C., & Posch, W. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.01.013 · Cited by 34
Anhydrous Nucleic Acid Nanoparticles for Storage and Handling at Broad Range of Temperatures
Tran, A., Chandler, M. R., Halman, J. R., Beasock, D., Fessler, A. B., McKeough, R. Q., Lam, P. A., Furr, D. P., Wang, J., Cedrone, E., et al. (2022) · Small · doi:10.1002/smll.202104814 · Cited by 27
A review of the safety and efficacy of current COVID-19 vaccines
Huang, Z., Su, Y., Zhang, T., & Xia, N. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0893-y · Cited by 32
Profiling post-COVID syndrome across different variants of SARS-CoV-2Preprint
Canas, L. S., Molteni, E., Deng, J., Sudre, C. H., Murray, B. A. K., Kerfoot, E., Antonelli, M., Chen, L., Rjoob, K. W. Y., Pujol, J. C., et al. (2022) · medRxiv · doi:10.1101/2022.07.28.22278159 · Cited by 25
Ditekemena, J., Mavoko, H. M., Obimpeh, M., Hees, S. V., Fodjo, J. N. S., Nkamba, D. M., Tshefu, A., Damme, W. V., Muyembe, J. J., & Colebunders, R. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18052525 · Cited by 25
Self-splicing RNA circularization facilitated by intact group I and II introns
Shen, Y. H., Li, B., Dong, L., Tang, W., Ren, J., Chen, F., Zheng, W., Yu, Y. F., Gao, L., & Wei, W. (2025) · Nature Communications · doi:10.1038/s41467-025-62607-y · Cited by 31
Ravichandran, B., Grimm, D. G., Krüger, M., Kopp, S., Infanger, M., & Wehland, M. (2021) · Physiological Reports · doi:10.14814/phy2.14800 · Cited by 32
Impact of COVID-19 vaccine on epilepsy in adult subjects: an Italian multicentric experience
Romozzi, M., Rollo, E., Quintieri, P., Dono, F., Evangelista, G., Consoli, S., Veleno, L., Anzellotti, F., Calvello, C., Costa, C., et al. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06100-0 · Cited by 25
Jawed, M., Khalid, A., Rubin, M., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab343 · Cited by 26
“Side effects reported include local reactions like redness, swelling, pain at injection site and systemic like fever, chills, fatigue, headache, new or worsening muscle pain, vomiting [12,13].”
BackgroundMethodHorve, P. F., Dietz, L. G., Northcutt, D., Stenson, J., & Wymelenberg, K. G. V. D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257689 · Cited by 23
COVID-19 vaccines for the European region: an unprecedented challenge
Kluge, H. H. P., & McKee, M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00709-1 · Cited by 24
First indication of the effect of COVID-19 vaccinations on the course of the outbreak in IsraelPreprint
De-Leon, H., Calderon‐Margalit, R., Pederiva, F., Ashkenazy, Y., & Gazit, D. (2021) · medRxiv · doi:10.1101/2021.02.02.21250630 · Cited by 25
Beyond the Individual: Community‐Centric Approaches to Increase Diversity in Biomedical Research
Brown, K. E., Fohner, A. E., & Woodahl, E. L. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2808 · Cited by 29
Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine
Leone, M. C., Canovi, S., Pilia, A., Casali, A., Depietri, L., Fasano, T., Colla, R., & Ghirarduzzi, A. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.01.017 · Cited by 26
The conundrum of COVID-19 mRNA vaccine–induced anaphylaxis
Khalid, M. B., & Frischmeyer‐Guerrerio, P. A. (2022) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2022.10.003 · Cited by 35
“Of note, these studies excluded participants who had a history of an allergic reaction to any vaccine component.(3,4) On the second day of public vaccine administration in the United Kingdom, 2 cases of anaphylaxis were confirmed, followed by 6 cases in the United States within the first 5 days of Pfizer-BioNTech vacc…”
SARS-CoV-2 Infection and the COVID-19 Pandemic Emergency: The Importance of Diagnostic Methods
Ciotti, M., Benedetti, F., Zella, D., Angeletti, S., Ciccozzi, M., & Bernardini, S. (2021) · Chemotherapy · doi:10.1159/000515343 · Cited by 30
Passamonti, F., Nicastri, E., Rocco, A. D., Guarini, A., Ibatici, A., Luminari, S., Mikulska, M., & Visco, C. (2022) · Hematological Oncology · doi:10.1002/hon.3086 · Cited by 28
Myocarditis following mRNA Covid-19 vaccination: A pooled analysis
Bellos, I., Karageorgiou, V., & Viskin, D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.017 · Cited by 31
Okuda, S., Hirooka, Y., & Sugiyama, M. (2021) · Vaccines · doi:10.3390/vaccines9080842 · Cited by 26
“The most frequent adverse effects reported after the administration of BNT162b2 were injection site pain, fever, fatigue, and headache, which occurred soon after vaccination and resolved shortly [3].”
BackgroundMethodInfluentialLoo, C., Lee, W., & Zhou, Q. T. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03520-1 · Cited by 34
“The first few mRNA vaccines encapsulated in lipid nanoparticles (LNPs) for Covid-19 infections were developed by BioNTech/Pfizer and Moderna for intramuscular administration [6, 7].”
MethodWieske, L., Kummer, L. Y. L., van Dam, K. P. J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02310-7 · Cited by 26
Mohammed, R. A., Garout, R. M., Wahid, S. M. A., et al. (2021) · Cureus · doi:10.7759/cureus.19222 · Cited by 26
“According to an article, headache, arm pain, and fever were self-limited yet some subjects used simple analgesics and antipyretics for relief [12].”
BackgroundSaá, P., Fink, R. V., Bakkour, S., Jin, J., Simmons, G., Muench, M. O., Dawar, H., Germanio, C. D., Hui, A. J., Wright, D. J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159876 · Cited by 31
“It is known that naive individuals are much more susceptible to severe disease than vaccinated individuals (22, 23).”
Affeldt, P., Koehler, F. C., Brensing, K. A., Gies, M., Platen, E., Adam, V., Butt, L., Grundmann, F., Heger, E., Hinrichs, S., et al. (2022) · Viruses · doi:10.3390/v14122646 · Cited by 27
“In particular, the messenger ribonucleic acid (mRNA) vaccines mRNA-1273 (Moderna, CA, USA) and BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York City, NY, USA) induce an effective antiviral humoral and cellular immune response [15,16].”
BackgroundMethodMcInerney, C. D., Kotzé, A., Bacon, S., Cutting, J., Fisher, L., Goldacre, B. M., Johnson, O. A., Kua, J., McGuckin, D., Mehrkar, A., et al. (2023) · Anaesthesia · doi:10.1111/anae.16001 · Cited by 28
Venerito, V., Stefanizzi, P., Fornaro, M., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2021-001847 · Cited by 26
Genetically engineered transfusable platelets using mRNA lipid nanoparticles
Leung, J., Strong, C., Badior, K. E., Robertson, M. K., Wu, X., Meledeo, M. A., Kang, E., Paul, M., Sato, Y., Harashima, H., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi0508 · Cited by 33
Distinct Clinical Features of Post-COVID-19 Vaccination Early-onset Graves’ Disease
di Filippo, L., Castellino, L., Allora, A., Frara, S., Lanzi, R., Perticone, F., Valsecchi, F., Vassallo, A., Giubbini, R., Rosen, C. J., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac550 · Cited by 26
Saharia, K., Husson, J. S., Niederhaus, S. V., Iraguha, T., Avila, S. V., Yoo, Y. J., Hardy, N. M., Fan, X., Omili, D. O., Crane, A., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1391 · Cited by 26
Frantz, P. N., Barinov, A., Ruffié, C., Combredet, C., Najburg, V., de Melo, G. D., Larrous, F., Kergoat, L., Teeravechyan, S., Jongkaewwattana, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26506-2 · Cited by 30
The landscape of neoantigens and its clinical applications: From immunobiology to cancer vaccines
Chakraborty, C., Majumder, A., Bhattacharya, M., Chatterjee, S., & Lee, S. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2024.100177 · Cited by 30
Biological recognition and cellular trafficking of targeted RNA-lipid nanoparticles
Escalona-Rayo, O., Papadopoulou, P., Slütter, B., & Kros, A. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103041 · Cited by 29
The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273
Markewitz, R. D. H., Pauli, D., Dargvainiene, J., Steinhagen, K., Engel, S., Herbst, V., Zapf, D., Krüger, C., Sharifzadeh, S. R., Schomburg, B., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.006 · Cited by 29
“This timeline observed by us can be correlated with the clinical observation that the cumulative incidences of unvaccinated and vaccinated individuals start to diverge 12 days [6,8] to 14 days [16] after the first dose.”
Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
Lange, B., Gerigk, M., & Tenenbaum, T. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2108076 · Cited by 26
Advances and Challenges in Antiviral Development for Respiratory Viruses
Jesús‐González, L. A. D., León‐Juárez, M., Lira-Hernández, F. I., Rivas-Santiago, B. T., Velázquez-Cervantes, M. A., Méndez-Delgado, I. M., Macias-Guerrero, D., Hernández-Castillo, J., Hernández-Rodríguez, X., Calderón-Sandate, D. N., et al. (2024) · Pathogens · doi:10.3390/pathogens14010020 · Cited by 27
“These approaches prioritize enhancing efficacy, safety, stability, and bioavailability while ensuring affordability, particularly for vulnerable populations and developing regions disproportionately affected by respiratory viral diseases [136–138].”
Acute encephalitis after COVID-19 vaccination: A case report and literature review
Gao, J.-J., Tseng, H., Lin, C.-L., Hsu, R.-F., Lee, M., & Liu, C. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2082206 · Cited by 28
“To combat the prevalence of SARS-CoV-2 infections, innovative mRNA vaccines have been developed, for which the efficacy and safety for preventing illness have been established.(6,7) However, vaccination-associated serious adverse events such as myelitis and acute disseminated encephalomyelitis have been described but…”
BackgroundKwok, W. C., Leung, I. S. H., Tam, T. C. C., Ho, J., Lam, D. C.-L., Ip, M., & Ho, P. (2023) · International Journal of COPD · doi:10.2147/copd.s394101 · Cited by 29
Konrath, K. M., Liaw, K., Wu, Y., Zhu, X., Walker, S. N., Xu, Z., Schultheis, K., Chokkalingam, N., Chawla, H., Du, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110318 · Cited by 27
Shin, H. E., Han, J., Shin, S., Bae, G., Son, B., Kim, T., Park, H. H., Park, C. G., & Park, W. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.004 · Cited by 36
Terpos, E., Karalis, V. D., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Gumeni, S., Malandrakis, P., Papanagnou, E., Kastritis, E., Trougakos, I. P., & Dimopoulos, M. A. (2021) · Life · doi:10.3390/life11101077 · Cited by 29
Ortiz-Egea, J. M., Sánchez, C. G., López-Jiménez, A., & Navarro, O. D. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03350-6 · Cited by 26
Keir, G., Maria, N. I., & Kirsch, C. (2021) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000287 · Cited by 27
Nicolete, V. C., Rodrigues, P. T., Johansen, I. C., Corder, R. M., Tonini, J., Cardoso, M. A., de Jesus, J. G., Claro, I. M., Faria, N. R., Sabino, É. C., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab410 · Cited by 40
“(3) Presence of antiSARS-CoV-2 IgG combined with at least one new or increased sign or symptom (fever, cough, shortness of breath, chills, muscle pain, loss of taste or smell, sore throat, diarrhea, or vomiting [21]) experienced since March 2020, as a proxy of clinically apparent COVID-19 during the follow-up.”
BackgroundMethodRecent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems
Wu, Z., Sun, W., & Qi, H. (2024) · Vaccines · doi:10.3390/vaccines12080873 · Cited by 35
“Since the out-break of COVID-19 and the success of two mRNA vaccines against SARS-COV-2, mRNA technology has quickly become the focus of vaccine research and development [2,3].”
BackgroundWalle, T., Bajaj, S., Kraske, J. A., Rösner, T., Cussigh, C. S., Kälber, K. A., Müller, L. J., Strobel, S. B., Burghaus, J., Kallenberger, S. M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00398-7 · Cited by 24
Heidenreich, P. A., Bhatt, A. S., Nazir, N. T., Schaffner, W., & Vardeny, O. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.003 · Cited by 42
Ghosh, S. B., Al-Sharify, Z. T., Maleka, M. F., Onyeaka, H. N., Maleke, M., Maolloum, A., Godoy, L., Meskini, M., Rami, M. R., Ahmadi, S., et al. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-21652-6 · Cited by 33
Pfeifle, A., Raman, S. N. T., Lansdell, C., Zhang, W., Tamming, L. A., Cecillon, J., Laryea, E., Patel, D., Wu, J., Gravel, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1020134 · Cited by 27
“While these particles have been explored in detail for mRNA delivery, including their use in the Comirnaty (PfizerBioNTech) and Spikevax (Moderna) COVID-19 vaccines, further research is required to evaluate their potential for DNA-based vaccination against a breadth of infectious agents (26, 27).”
BackgroundSousa, D. A., Gaspar, R., Ferreira, C. J. O., Baltazar, F., Rodrigues, L. R., & Silva, B. F. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051087 · Cited by 27
“A related type of lipid nanodelivery system, using ionizable lipids that are cationic only at lower pH [22,43,44], is the base of current mRNA vaccines being used worldwide for COVID-19 prevention [45,46].”
BackgroundZacay, G., Shasha, D., Bareket, R., Kadim, I., Sikron, F. H., Tsamir, J., Mossinson, D., & Heymann, A. D. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab262 · Cited by 31
Aspirin in COVID-19: Pros and Cons
Zareef, R. O., Diab, M. M., Saleh, T. A., Makarem, A., Younis, N. K., Bitar, F. F., & Arabi, M. T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.849628 · Cited by 27
“Vaccines developed against SARS-CoV-2 virus have shown effective reduction in transmission rate as well as the pattern of hospitalization, ventilation and mortality, as evident by the clinical trials (Polack et al., 2020; Voysey et al., 2021).”
BackgroundmRNA vaccines take on immune tolerance
Wardell, C. M., & Levings, M. K. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00880-0 · Cited by 27
Challenges of evaluating and modelling vaccination in emerging infectious diseases
Madewell, Z. J., Dean, N. E., Berlin, J. A., COPLAN, P. M., Davis, K. J., Struchiner, C. J., & Halloran, M. E. (2021) · Epidemics · doi:10.1016/j.epidem.2021.100506 · Cited by 31
Theranostic Lipid Nanoparticles for Renal Cell Carcinoma
Mao, X., Wang, G., Wang, Z., Duan, C., Wu, X., & Xu, H. (2023) · Advanced Materials · doi:10.1002/adma.202306246 · Cited by 30
Tsapepas, D. S., Husain, S. A., King, K. L., et al. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab272 · Cited by 26
“Vaccination represents an important strategy for prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and severe disease.(3,4) However, limited vaccine access and vaccine hesitancy complicate efforts to rapidly expand vaccination.”
BackgroundNanotheranostics Revolutionizing Gene Therapy: Emerging Applications in Gene Delivery Enhancement
Guzmán-Sastoque, P., Rodríguez, C. F., Monsalve, M. C., Castellanos, S., Manrique-Moreno, A., Reyes, L. H., & Cruz, J. C. (2025) · Journal of Nanotheranostics · doi:10.3390/jnt6020010 · Cited by 32
A Novel Vaccine Selection Decision-Making Model (VSDMM) for COVID-19
Abdelwahab, S. F., Issa, U. H., & Ashour, H. M. (2021) · Vaccines · doi:10.3390/vaccines9070718 · Cited by 27
“The selected vaccines were the vaccines of Pfizer BioNTech [27], NIH-Moderna [28], AstraZeneca [29,30], Sinopharm [31], Sputnik V [32], and Janssen Research & Development [33].”
MethodMyocarditis Following COVID-19 Vaccination: A Systematic Review (October 2020–October 2021)
Lee, S. Y. A., Balakrishnan, I. D., Khoo, C. Y., Ng, C. T., Loh, J. K., Chan, L. L., Teo, L. L., & Sim, D. K. L. (2022) · Heart Lung and Circulation · doi:10.1016/j.hlc.2022.02.002 · Cited by 30
“myocarditis [48,49], although there was one case of paroxysmal ventricular arrhythmia in the BNT162b2 vaccine trial.”
Changing epidemiology of COVID-19: potential future impact on vaccines and vaccination strategies
Ulrichs, T., Rolland, M., Wu, J., Nunes, M. C., Guerche‐Séblain, C. E., & Chit, A. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2346589 · Cited by 30
Borgoyakova, M. B., Карпенко, Л. И., Рудометов, А. П., Volosnikova, E. A., Merkuleva, I. A., Starostina, E. V., Zadorozhny, A. M., Исаева, А. А., Nesmeyanova, V. S., Васильевич, Ш. Д., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042188 · Cited by 30
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.